FOXO Stock Overview
Develops epigenetic biomarkers technology solutions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
FOXO Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.17 |
| 52 Week High | US$2.07 |
| 52 Week Low | US$0.13 |
| Beta | 2.01 |
| 11 Month Change | 13.67% |
| 3 Month Change | -35.11% |
| 1 Year Change | -83.38% |
| 33 Year Change | -99.82% |
| 5 Year Change | n/a |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| FOXO | US Software | US Market | |
|---|---|---|---|
| 7D | -12.7% | -2.3% | -0.7% |
| 1Y | -83.4% | 30.5% | 32.5% |
Return vs Industry: FOXO underperformed the US Software industry which returned 32.9% over the past year.
Return vs Market: FOXO underperformed the US Market which returned 34.1% over the past year.
Price Volatility
| FOXO volatility | |
|---|---|
| FOXO Average Weekly Movement | 9.5% |
| Software Industry Average Movement | 7.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: FOXO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FOXO's weekly volatility has decreased from 17% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Mark White | foxotechnologies.com |
FOXO Technologies Inc. develops epigenetic biomarkers technology solutions in the United States. The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers.
FOXO Technologies Inc. Fundamentals Summary
| FOXO fundamental statistics | |
|---|---|
| Market cap | US$2.43m |
| Earnings (TTM) | -US$13.06m |
| Revenue (TTM) | US$155.00k |
15.2x
P/S Ratio-0.2x
P/E RatioIs FOXO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FOXO income statement (TTM) | |
|---|---|
| Revenue | US$155.00k |
| Cost of Revenue | US$163.00k |
| Gross Profit | -US$8.00k |
| Other Expenses | US$13.06m |
| Earnings | -US$13.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | -5.16% |
| Net Profit Margin | -8,428.39% |
| Debt/Equity Ratio | -53.6% |
How did FOXO perform over the long term?
See historical performance and comparison